Investor Relations

Overview

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

Upcoming
More events are coming soon.
Prior

June 17, 2019 8:00 AM EDT
Ruxolitinib Cream: Phase 2 Data in Vitiligo Webcast

June 11, 2019 2:00 PM PDT
Goldman Sachs 40th Annual Global Healthcare Conference

May 21, 2019 10:30 AM EDT
RBC Capital Markets Healthcare Conference

SEC Filings

Filing date Description Filing Group View

Statement of changes in beneficial ownership of securities

3,4,5

An amendment to a SC 13D filing

3,4,5

Statement of changes in beneficial ownership of securities

3,4,5

Investor Contacts

Michael Booth D.Phil
Vice President, Investor Relations
Phone: 302.498.5914
E-mail: mbooth@incyte.com

Lauren Ayala
Senior Director, Investor Relations
Phone: 302.498.6141
E-mail: layala@incyte.com

Computershare
P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536